Avanos Medical Inc

Market Summary

USD21.50+0.28

Market Closed

1.32%

AVNS Alerts

Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

AVNS Stock Price

View Fullscreen

AVNS RSI Chart

AVNS Alerts

Big fall in Revenue (Y/Y)
Big fall in earnings (Y/Y)
Losses in recent quarter

AVNS Valuation

Market Cap

985.1M

Price/Earnings (Trailing)

-17.78

Price/Sales (Trailing)

1.29

EV/EBITDA

13.58

Price/Free Cashflow

18.45

AVNS Price/Sales (Trailing)

AVNS Profitability

EBT Margin

4.41%

Return on Equity

-2.92%

Return on Assets

-2.16%

Free Cashflow Yield

5.42%

AVNS Fundamentals

AVNS Revenue

Revenue (TTM)

766.0M

Revenue Y/Y

-15.24%

Revenue Q/Q

1.12%

AVNS Earnings

Earnings (TTM)

-55.4M

Earnings Y/Y

-123.57%

Earnings Q/Q

94.57%

Price Action

Last 7 days

-0.6%

Last 30 days

20.0%

Last 90 days

-1.0%

Trailing 12 Months

-20.3%

How does AVNS drawdown profile look like?

AVNS Financial Health

Current Ratio

3.16

Debt/Equity

0.16

Debt/Cashflow

0.26

AVNS Investor Care

Buy Backs (1Y)

0.15%

Diluted EPS (TTM)

-1.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	798.3M	796.8M	766.0M	0
2022	761.3M	745.8M	763.8M	804.0M
2021	715.1M	737.8M	736.2M	744.6M
2020	713.8M	705.3M	719.6M	714.8M
2019	660.1M	671.4M	677.7M	697.6M
2018	622.3M	634.1M	648.7M	652.3M
2017	577.5M	588.9M	600.3M	611.6M
2016	523.3M	537.6M	551.9M	566.2M
2015	1.7B	1.6B	1.6B	509.0M
2014	1.7B	1.7B	1.7B	1.7B
2013	1.7B	1.7B	1.7B	1.7B
2012	0	0	0	1.7B

Get all data in R, Python etc through our Historical Stock Data APIs

Latest Insider Trading transactions for AVNS

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 30, 2023	hurley john joseph	sold (taxes)	-10,009	17.81	-562	principal accounting officer
Jul 20, 2023	james mojirade	sold (taxes)	-17,337	26.15	-663	svp, general counsel
May 08, 2023	woody joseph fralin	sold (taxes)	-1,372,430	23.97	-57,256	chief executive officer
May 08, 2023	holbrook kerr	sold (taxes)	-42,474	23.97	-1,772	svp, chief commercial officer
May 08, 2023	greiner michael	sold (taxes)	-352,599	23.97	-14,710	svp - chief financial officer
Mar 06, 2023	james mojirade	acquired	-	-	20,339	svp, general counsel
Mar 06, 2023	sarker arjun ranjan	acquired	-	-	4,562	senior vp, international
Mar 06, 2023	greiner michael	acquired	-	-	36,350	svp - chief financial officer
Mar 06, 2023	holbrook kerr	sold (taxes)	-44,815	29.62	-1,513	svp, gm chronic care
Mar 06, 2023	hurley john joseph	sold (taxes)	-947	29.62	-32.00	principal accounting officer

Which funds bought or sold AVNS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Nov 24, 2023	DEUTSCHE BANK AG\	reduced	-51.23	-791,988	497,514	-%
Nov 22, 2023	KBC Group NV	unchanged	-	-	92,000	-%
Nov 22, 2023	Public Sector Pension Investment Board	reduced	-30.06	-945,838	1,171,420	0.01%
Nov 22, 2023	Graham Capital Management, L.P.	sold off	-100	-478,253	-	-%
Nov 21, 2023	Walleye Capital LLC	new	-	339,433	339,433	-%
Nov 21, 2023	COMERICA BANK	new	-	571,197	571,197	-%
Nov 17, 2023	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-220,404	-	-%
Nov 16, 2023	Creative Planning	new	-	5,076	5,076	-%
Nov 16, 2023	Financial Gravity Asset Management, Inc.	sold off	-100	-732	-	-%
Nov 15, 2023	JANE STREET GROUP, LLC	sold off	-100	-293,352	-	-%

Latest Funds Activity

Are funds buying AVNS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVNS

No. of Funds

Schedule 13G FIlings of Avanos Medical Inc

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2023	rgm capital, llc	5.71%	2,653,104	SC 13G/A
Feb 09, 2023	vanguard group inc	11.83%	5,500,000	SC 13G/A
Feb 08, 2023	paradice investment management llc	5.0%	2,343,232	SC 13G/A
Jan 26, 2023	blackrock inc.	16.3%	7,571,048	SC 13G/A
Jan 20, 2023	blackrock inc.	16.3%	7,571,048	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	0.2%	133,980	SC 13G/A
Feb 11, 2022	champlain investment partners, llc	2.44%	1,174,483	SC 13G/A
Feb 11, 2022	rgm capital, llc	6.08%	2,930,872	SC 13G
Feb 09, 2022	vanguard group inc	10.84%	5,221,786	SC 13G/A
Feb 04, 2022	wellington management group llp	2.75%	1,325,674	SC 13G/A

Recent SEC filings of Avanos Medical Inc

View All Filings

Date Filed	Form Type	Document
Nov 01, 2023	8-K	Current Report
Nov 01, 2023	10-Q	Quarterly Report
Oct 31, 2023	4	Insider Trading
Oct 02, 2023	8-K	Current Report

Peers (Alternatives to Avanos Medical Inc)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	178.8B	40.0B	10.05%	-2.88%	34.63	4.47	-11.26%	-34.57%
BDX	71.3B	19.4B	-6.71%	1.22%	44.09	3.79	2.66%	-16.58%
BAX	18.4B	15.0B	11.91%	-35.29%	7.11	1.23	3.01%	209.09%
ALGN	16.8B	3.8B	-13.48%	11.82%	46.33	4.42	-1.48%	-28.97%
MID-CAP
HSIC	9.1B	12.6B	2.80%	-13.35%	19.86	0.72	-0.94%	-29.54%
BIO	8.9B	2.7B	7.69%	-22.67%	-56.07	3.28	-3.01%	97.36%
ATR	8.4B	3.4B	4.90%	20.89%	30	2.45	3.13%	18.17%
XRAY	6.6B	3.9B	-1.54%	1.10%	-30.43	1.69	-2.62%	73.28%
PDCO	3.1B	6.5B	5.03%	11.86%	14.6	0.48	1.83%	10.70%
AXNX	2.9B	342.6M	11.80%	-12.52%	-240.39	8.41	42.19%	84.14%
SMALL-CAP
AHCO	1.2B	3.1B	19.36%	-60.32%	-2.73	0.37	7.95%	-550.16%
ANIK	310.6M	163.3M	13.17%	-30.31%	-12.64	1.9	7.14%	-56.09%
ANGO	280.7M	335.9M	7.28%	-49.08%	43.55	0.84	4.71%	116.39%
APYX	88.3M	50.3M	4.17%	45.35%	-5.83	1.76	3.23%	20.81%
AEMD	4.2M	3.8M	13.42%	-61.23%	-0.36	1.11	17.30%	10.67%

Avanos Medical Inc News

Latest updates

Defense World • 27 Nov 2023 • 10:57 am • 13 hours ago

Avanos Medical, Inc. (NYSE:AVNS) Stock Position Raised by ...

Zacks Investment Research • 02 Nov 2023 • 07:00 am • 25 days ago

Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract

Houston Chronicle • 01 Nov 2023 • 07:00 am • 26 days ago

Avanos Medical: Q3 Earnings Snapshot

Investing.com UK • 01 Nov 2023 • 07:00 am • 26 days ago

Garmin, Apollo Global Management, Trane Technologies, Scotts ...

Yahoo Finance • 31 Oct 2023 • 07:00 am • 27 days ago

Why Avanos (AVNS) Might Surprise This Earnings Season

Nasdaq • 27 Oct 2023 • 07:00 am • 31 days ago

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

Nasdaq • 26 Oct 2023 • 07:00 am • 32 days ago

Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?

Yahoo Finance • 25 Oct 2023 • 07:00 am • 33 days ago

Avanos Medical, Inc. to Webcast Conference Call Discussing Third Quarter 2023 Financial Results

Nasdaq • 25 Oct 2023 • 07:00 am • 33 days ago

DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?

Yahoo Finance • 10 Oct 2023 • 07:00 am • 48 days ago

Shareholders in Avanos Medical (NYSE:AVNS) are in the red if they invested five years ago

Yahoo Finance • 02 Oct 2023 • 07:00 am • 56 days ago

AirLife Completes Acquisition of Avanos Medical’s Respiratory Health Business

Yahoo Finance • 11 Aug 2023 • 07:00 am • 3 months ago

Avanos Medical, Inc. (NYSE:AVNS) Q2 2023 Earnings Call Transcript

Zacks Investment Research • 26 Jul 2023 • 07:00 am • 4 months ago

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

Yahoo Finance • 25 Jul 2023 • 07:00 am • 4 months ago

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

Nasdaq • 19 Jul 2023 • 07:00 am • 4 months ago

Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?

Financials for Avanos Medical Inc

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Revenue	1.1%	171,300,000	169,400,000	191,700,000	233,550,000	202,100,000	170,900,000	197,400,000	193,400,000	184,100,000	186,400,000	180,700,000	185,000,000	185,700,000	163,700,000	180,400,000	189,800,000	171,400,000	172,200,000	164,200,000	169,900,000	165,100,000
Gross Profit	-2.4%	95,500,000	97,800,000	104,500,000	124,300,000	110,100,000	101,600,000	106,600,000	98,750,000	90,200,000	85,700,000	91,300,000	86,500,000	95,800,000	86,500,000	102,100,000	109,700,000	95,000,000	98,700,000	98,800,000	100,400,000	104,700,000
S&GA Expenses	-15.4%	78,700,000	93,000,000	92,700,000	84,550,000	82,100,000	83,200,000	90,100,000	75,200,000	75,000,000	76,700,000	73,400,000	82,200,000	82,400,000	76,900,000	91,100,000	103,600,000	94,400,000	94,700,000	106,400,000	87,900,000	86,300,000
R&D Expenses	-10.3%	6,100,000	6,800,000	7,900,000	7,700,000	7,300,000	7,600,000	7,800,000	7,600,000	8,400,000	8,000,000	8,300,000	9,600,000	8,200,000	7,700,000	9,400,000	8,400,000	9,600,000	9,500,000	10,200,000	10,600,000	10,500,000
EBITDA Margin	-100.0%	-	0.12	0.15	0.15	0.15	0.13	0.08	0.06	-0.04	-0.04	-0.01	0.00	0.05	-0.01	-0.01	-0.02	-	-	-	-	-
Interest Expenses	34.3%	4,700,000	3,500,000	3,500,000	3,000,000	3,000,000	2,700,000	1,300,000	700,000	900,000	900,000	800,000	2,700,000	4,300,000	4,300,000	4,300,000	4,300,000	3,500,000	3,500,000	3,700,000	3,500,000	4,200,000
Income Taxes	875.0%	6,200,000	-800,000	100,000	8,350,000	300,000	2,800,000	1,900,000	14,800,000	38,000,000	-46,000,000	-5,800,000	-800,000	-23,500,000	-2,900,000	-6,700,000	-400,000	-8,800,000	-3,300,000	-5,600,000	-6,700,000	800,000
Earnings Before Taxes	49.0%	-2,600,000	-5,100,000	-400,000	29,100,000	16,000,000	7,600,000	7,300,000	26,300,000	2,700,000	-7,500,000	-14,200,000	-49,800,000	-4,200,000	-	-	-6,500,000	-20,300,000	-11,300,000	-25,900,000	-9,400,000	5,000,000
EBT Margin	-100.0%	-	0.04	0.07	0.08	0.08	0.07	0.04	0.01	-0.09	-0.10	-0.08	-0.08	-0.03	-0.09	-0.09	-0.09	-	-	-	-	-
Net Income	94.6%	-3,700,000	-68,100,000	-500,000	16,900,000	15,700,000	12,500,000	5,400,000	11,500,000	-35,300,000	38,500,000	-8,400,000	-49,000,000	19,300,000	-3,000,000	3,700,000	-6,100,000	-11,500,000	-8,000,000	-20,300,000	-2,200,000	4,200,000
Net Income Margin	100.0%	-	-0.05	0.05	0.06	0.06	-0.01	0.02	0.01	-0.07	0.00	-0.05	-0.04	0.02	-0.02	-0.03	-0.07	-	-	-	-	-
Free Cashflow	100.0%	-	-2,600,000	-6,800,000	33,700,000	28,400,000	27,000,000	1,800,000	52,100,000	23,200,000	15,300,000	-3,300,000	1,100,000	1,100,000	1,100,000	-5,800,000	-2,900,000	-	-	-	-	-

Balance Sheet
(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Assets	3.5%	1,725	1,667	1,735	1,787	1,775	1,753	1,767	1,604	1,598	1,683	1,649	1,673	1,799	1,756	1,764	1,800	1,808	1,783	1,834	1,833	1,845
Current Assets	3.5%	525	507	454	500	470	437	439	428	405	444	448	467	568	517	524	539	547	573	660	714	737
Cash Equivalents	30.9%	107	82.00	96.00	128	117	107	104	119	98.00	100	100	112	180	185	188	205	214	288	348	385	412
Inventory	5.6%	157	148	200	132	194	169	158	159	158	160	165	169	184	174	153	146	145	134	130	121	121
Net PPE	-4.7%	117	123	164	119	163	164	167	168	170	172	173	175	177	179	179	185	182	174	160	154	137
Goodwill	3.8%	792	763	822	760	824	825	826	802	802	803	802	803	801	800	800	801	19.00	14.00	784	784	787
Liabilities	16.4%	503	432	436	496	512	501	510	333	336	387	396	416	509	494	507	534	541	507	554	536	544
Current Liabilities	6.4%	171	161	159	186	162	151	153	139	129	158	155	166	179	176	189	213	218	187	238	264	266
Long Term Debt	27.1%	258	203	205	226	248	249	254	130	145	165	175	180	249	248	248	248	248	248	248	248	-
LT Debt, Current	0%	6.00	6.00	6.00	6.00	6.00	5.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	226	-	-	-	130	-	-	-	-	-	-	-	248	-	-	-	248	248
Shareholder's Equity	-1.0%	1,222	1,235	1,299	1,291	1,264	1,259	1,263	1,271	1,267	1,302	1,257	1,262	1,290	1,262	1,257	1,273	1,267	1,277	1,280	1,297	1,300
Retained Earnings	-1.2%	-325	-321	-253	-253	-270	-293	-304	-303	-320	-285	-323	-309	-268	-287	-284	-288	-282	-270	-262	-242	-240
Additional Paid-In Capital	0.3%	1,660	1,655	1,651	1,646	1,642	1,637	1,633	1,629	1,626	1,621	1,617	1,609	1,604	1,600	1,596	1,594	1,592	1,587	1,583	1,578	1,576
Shares Outstanding	-0.9%	46.00	47.00	47.00	47.00	46.00	47.00	47.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	48.00	47.00	47.00

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3
Cashflow From Operations	1219.2%	29,100	-2,600	-6,800	33,700	28,400	27,000	1,800	52,100	23,200	15,300	-3,300	1,100	1,100	1,100	-5,800	-2,900	-16,600	-31,900	-23,100	-7,400	-67,800
Share Based Compensation	0%	3,900	3,900	4,000	4,000	4,100	4,000	3,800	3,000	3,500	3,600	3,100	3,200	3,400	3,000	2,500	1,700	2,800	1,800	4,200	2,500	2,400
Cashflow From Investing	-652.3%	-48,900	-6,500	-4,000	-4,900	-4,700	-4,100	-121,700	-4,700	-4,800	-5,800	-5,700	-5,100	-7,000	-6,900	-5,200	-8,100	-57,600	-29,900	-12,500	-17,800	-56,500
Cashflow From Financing	1239.0%	46,700	-4,100	-22,100	-21,900	-10,200	-16,900	105,700	-25,800	-19,200	-10,100	-200	-68,300	-2,000	300	-	-100	2,500	800	-1,700	-1,600	5,400
Buy Backs	253.8%	9,200	2,600	1,100	400	11,000	14,700	19,400	10,900	100	500	-	500	100	300	-	200	100	1,400	1,900	300	-

AVNS Income Statement

2023-09-30

CONDENSED CONSOLIDATED INCOME STATEMENTS - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net Sales	$ 171.3	$ 172.3	$ 500.0	$ 502.5
Cost of products sold	75.8	72.1	215.3	211.2
Gross Profit	95.5	100.2	284.7	291.3
Research and development	6.1	7.1	20.4	22.0
Selling and general expenses	78.7	78.3	260.5	247.8
Other expense, net	9.5	2.0	10.8	2.6
Operating Income (Loss)	1.2	12.8	(7.0)	18.9
Interest income	0.9	0.3	1.9	0.5
Interest expense	(4.7)	(3.0)	(11.7)	(7.0)
(Loss) Income Before Income Taxes	(2.6)	10.1	(16.8)	12.4
Income tax (provision) benefit	(6.2)	0.9	(4.1)	(0.6)
(Loss) Income from Continuing Operations	(8.8)	11.0	(20.9)	11.8
Income (loss) from discontinued operations, net of tax	5.1	4.7	(51.4)	21.8
Net (Loss) Income	$ (3.7)	$ 15.7	$ (72.3)	$ 33.6
Basic (Loss) Earnings Per Share
Continuing operations- basic (in dollars per share)	$ (0.19)	$ 0.24	$ (0.45)	$ 0.25
Discontinued operations- basic (in dollars per share)	0.11	0.10	(1.10)	0.46
Basic (Loss) Earnings Per Share (in dollars per share)	(0.08)	0.34	(1.55)	0.71
Diluted (Loss) Earnings Per Share
Continuing operations- diluted (in dollars per share)	(0.19)	0.23	(0.45)	0.25
Discontinued operations- diluted (in dollars per share)	0.11	0.10	(1.10)	0.46
Diluted (Loss) Earnings Per Share (in dollars per share)	$ (0.08)	$ 0.33	$ (1.55)	$ 0.71

AVNS Balance Sheet

2023-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 107.1	$ 127.7
Accounts receivable, net of allowances	145.2	167.9
Inventories	156.6	132.3
Prepaid and other current assets	13.6	13.9
Assets held for sale	102.1	58.0
Total Current Assets	524.6	499.8
Property, Plant and Equipment, net	116.8	118.6
Operating Lease Right-of-Use Assets	27.1	27.5
Goodwill	791.5	760.3
Other Intangible Assets, net	242.2	234.2
Deferred Tax Assets	4.3	4.6
Other Assets	18.4	17.6
Assets Held for Sale	0.0	124.3
TOTAL ASSETS	1,724.9	1,786.9
Current Liabilities
Current portion of long-term debt	6.2	6.2
Current portion of operating lease liabilities	12.7	12.0
Trade accounts payable	52.1	67.9
Accrued expenses	97.2	98.9
Liabilities held for sale	2.5	0.8
Total Current Liabilities	170.7	185.8
Long-Term Debt	258.3	226.3
Operating Lease Liabilities	29.5	32.5
Deferred Tax Liabilities	28.7	25.4
Other Long-Term Liabilities	15.6	23.5
Liabilities Held for Sale	0.0	2.2
Total Liabilities	502.8	495.7
Commitments and Contingencies
Stockholders’ Equity
Preferred stock - $0.01 par value - authorized 20,000,000 shares, none issued	0.0	0.0
Common stock - $0.01 par value - authorized 300,000,000 shares, 46,425,157 outstanding as of September 30, 2023 and 46,528,907 outstanding as of December 31, 2022	0.5	0.5
Additional paid-in capital	1,659.7	1,646.4
Accumulated deficit	(325.4)	(253.1)
Treasury stock	(79.7)	(66.8)
Accumulated other comprehensive loss	(33.0)	(35.8)
Total Stockholders’ Equity	1,222.1	1,291.2
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 1,724.9	$ 1,786.9

About Avanos Medical Inc

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy and OrthogenRx's knee osteoarthritis pain relief injection products. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

CEO	Mr. Joseph F. Woody
WEBSITE	avanos.com
EMPLOYEES	4044

Avanos Medical Inc Frequently Asked Questions

What is the ticker symbol for Avanos Medical Inc?

Ticker symbol for Avanos Medical Inc is AVNS.

What is the market capital of Avanos Medical Inc (AVNS)?

As of Fri Nov 24 2023, market cap of Avanos Medical Inc is 985.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVNS stock?

You can check AVNS's fair value in chart. The fair value of Avanos Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avanos Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVNS so that you know how good or bad the model has been in the past so you can discard it if needed.

Is Avanos Medical Inc stock overpriced or underpriced?

The fair value guage provides a quick view whether AVNS is over valued or under valued. Whether Avanos Medical Inc is cheap or expensive depends on the assumptions which impact Avanos Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVNS.

What is Avanos Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 24 2023, AVNS's PE ratio (Price to Earnings) is -17.78 and Price to Sales (PS) ratio is 1.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AVNS PE ratio will change depending on the future growth rate expectations of investors.

Market Summary

AVNS Alerts

AVNS Stock Price

AVNS RSI Chart

AVNS Alerts

AVNS Valuation

AVNS Price/Sales (Trailing)

AVNS Profitability

AVNS Fundamentals

AVNS Revenue

AVNS Earnings

Price Action

How does AVNS drawdown profile look like?

AVNS Financial Health

AVNS Investor Care

Historical Charts for Stock Metrics

Latest Insider Trading transactions for AVNS

Which funds bought or sold AVNS recently?

Latest Funds Activity

Schedule 13G FIlings of Avanos Medical Inc

Recent SEC filings of Avanos Medical Inc

Peers (Alternatives to Avanos Medical Inc)

Avanos Medical Inc News

Financials for Avanos Medical Inc

Income Statement (Last 12 Months)

Balance Sheet.css-zgnqz2{margin:0;font-family:"Roboto","Helvetica","Arial",sans-serif;font-weight:400;font-size:0.75rem;line-height:1.66;letter-spacing:0.03333em;color:#595959;}(In Millions)

Cashflow (Last 12 Months)

AVNS Income Statement

AVNS Balance Sheet

About Avanos Medical Inc

Avanos Medical Inc Frequently Asked Questions

What is the ticker symbol for Avanos Medical Inc?

What is the market capital of Avanos Medical Inc (AVNS)?

What is the fair value of AVNS stock?

Is Avanos Medical Inc stock overpriced or underpriced?

What is Avanos Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

Balance Sheet
(In Millions)